---
layout: minimal-medicine
title: Lurbinectedin
---

# Lurbinectedin
### Generic Name
Lurbinectedin

### Usage
Lurbinectedin is primarily used to treat adult patients with metastatic small-cell lung cancer (SCLC).  This treatment is specifically indicated for individuals whose cancer has progressed despite prior treatment with platinum-based chemotherapy.  Currently, there are no approved uses for Lurbinectedin in other cancers or in pediatric populations.

### Dosage
Lurbinectedin is administered intravenously (IV).  Treatment should only begin if the absolute neutrophil count (ANC) is at least 1500/mm³ and the platelet count is at least 100,000/mm³.

For metastatic SCLC, the typical dose is 3.2 mg/m² given once every 21 days.  Treatment continues until the disease progresses or unacceptable toxicity occurs.  Dose adjustments are necessary based on several factors:

* **Hepatic Impairment:** For mild impairment (bilirubin ≤ ULN and AST > ULN, or bilirubin 1-1.5 times ULN and any AST level), no adjustment is needed.  For moderate or severe impairment (bilirubin >1.5 times ULN and any AST level), the manufacturer's labeling does not provide specific dosage adjustments.  However, careful monitoring is crucial.

* **Renal Impairment:**  For creatinine clearance (CrCl) of 30-89 mL/min, no dosage adjustment is explicitly recommended by the manufacturer, although studies show no significant pharmacokinetic differences in mild to moderate impairment.  For CrCl <30 mL/min, no dosage adjustment is provided.  Close monitoring is recommended.

* **Obesity:**  Follow American Society of Clinical Oncology (ASCO) guidelines. Use actual body weight for BSA or weight-based dosing, especially when aiming for curative treatment. Manage toxicities as you would in patients with BMI <30 kg/m².  Consider resuming full weight-based dosing if toxicity (e.g., hepatic or renal impairment) is resolved.

* **Toxicity Management:** Dose reductions for adverse reactions are as follows:  Initial dose 3.2 mg/m², first reduction to 2.6 mg/m², second reduction to 2 mg/m².  If a 2 mg/m² dose is not tolerated, or if a dose delay of more than 2 weeks is required, Lurbinectedin should be permanently discontinued.  Specific adjustments are also made for hematologic toxicity (neutropenia and thrombocytopenia).  Refer to your healthcare provider's guidelines for detailed protocols on dosage adjustments based on specific adverse effects.

**Pediatric Dosage:** The safety and effectiveness of Lurbinectedin have not been established in children.


### Side Effects
Common side effects (>10%) include:

* Fatigue
* Peripheral neuropathy
* Decreased serum albumin, magnesium, and sodium levels
* Increased serum glucose level
* Abdominal pain, constipation, decreased appetite, diarrhea, nausea, and vomiting
* Anemia, leukopenia, lymphocytopenia, and neutropenia
* Increased serum AST and ALT levels
* Musculoskeletal pain
* Increased serum creatinine level
* Cough, dyspnea, and respiratory tract infection
* Fever


Less common but potentially serious side effects (1-10%) include:

* Headache
* Chest pain
* Febrile neutropenia
* Thrombocytopenia
* Sepsis
* Pneumonia

Report any side effects to your healthcare provider immediately.


### How it Works
Lurbinectedin is an alkylating agent and a selective inhibitor of oncogenic transcription.  It binds to specific guanine residues in DNA's minor groove, creating adducts and bending the DNA helix. This process disrupts the function of DNA-binding proteins, including some transcription factors and DNA repair pathways.  The resulting inhibition of oncogenic transcription leads to the death of tumor cells (apoptosis).


### Precautions
* **Pregnancy:** Lurbinectedin can harm a developing fetus.  Women of childbearing age should use effective contraception during and for six months after treatment.  Male partners of women who can become pregnant should use effective contraception during treatment and for four months after the final dose.  Breastfeeding is not recommended during therapy and for two weeks after the final dose.
* **Drug Interactions:** Lurbinectedin's metabolism is affected by CYP3A4 inducers and inhibitors.  Concomitant use of strong or moderate CYP3A4 inducers or inhibitors should be avoided or carefully managed with dose adjustments as needed, in consultation with a physician. Numerous other drug interactions are possible; careful review of potential interactions with other medications is required. Consult a healthcare professional for a complete list.
* **Myelosuppression & Hepatotoxicity:** Lurbinectedin can cause bone marrow suppression (myelosuppression) and liver damage (hepatotoxicity). Regular blood tests are essential to monitor blood counts and liver function.
* **Other Precautions:**  Administer the intravenous infusion over 60 minutes. Avoid extravasation.  Antiemetic prophylaxis is generally recommended.


### FAQs

* **Q: How is Lurbinectedin stored?** A: Consult your pharmacist or refer to the medication's packaging for specific storage instructions.
* **Q: Can I take other medications while on Lurbinectedin?** A:  It's crucial to inform your doctor about all medications, supplements, and herbal remedies you're taking. Some interactions can be serious.
* **Q: What should I do if I miss a dose?** A: Contact your doctor immediately for guidance.
* **Q: How long will I be on Lurbinectedin?** A: The duration of treatment depends on your response to the medication and your overall health status. This is determined by your oncologist.
* **Q: What are the long-term effects of Lurbinectedin?** A: Long-term effects are still being studied, but regular monitoring for potential side effects is crucial.  Discuss any long-term concerns with your doctor.
* **Q: Is Lurbinectedin suitable for all patients with SCLC?** A:  No. It's specifically for patients whose cancer has progressed after platinum-based chemotherapy.  Your physician will determine your eligibility.


**Disclaimer:** This information is intended for educational purposes only and should not be considered medical advice.  Always consult your healthcare provider for diagnosis, treatment, and management of medical conditions.  The information provided here may not be exhaustive and may not cover all possible uses, precautions, drug interactions, or adverse effects. Always refer to the most current product labeling and seek professional medical advice before making any decisions related to your health or treatment.
